Zepbound, Eli Lilly's weight-loss drug, showed promising results in reducing breathing problems in patients with obstructive sleep apnea, potentially increasing insurance coverage. [ more ]
Users of New Weight Loss Drug Had Lower Blood Pressure in Study
Tirzepatide, a weight loss drug, was found to significantly lower blood pressures after 36 weeks of use.
The study assessed tirzepatide's effects on weight loss and found that participants taking the drug had lower blood pressures when measured with a 24-hour monitor. [ more ]
As Eli Lilly Wades Into Telehealth for Weight Loss, Doctors Are Wary
Eli Lilly has launched a new platform called LillyDirect to make it easier for patients to access its weight loss drug, Zepbound, by connecting them with telehealth providers and prescription delivery services.
The platform aims to ensure patients receive brand-name drugs and not counterfeit versions, as well as access coupons to lower the cost of the medication. [ more ]
As Eli Lilly Wades Into Telehealth for Weight Loss, Doctors Are Wary
Eli Lilly has launched a new platform called LillyDirect to make it easier for patients to access its weight loss drug, Zepbound, by connecting them with telehealth providers and prescription delivery services.
The platform aims to ensure patients receive brand-name drugs and not counterfeit versions, as well as access coupons to lower the cost of the medication. [ more ]
As Eli Lilly Wades Into Telehealth for Weight Loss, Doctors Are Wary
Eli Lilly has launched a new platform called LillyDirect to make it easier for patients to access its weight loss drug, Zepbound, by connecting them with telehealth providers and prescription delivery services.
The platform aims to ensure patients receive brand-name drugs and not counterfeit versions, as well as access coupons to lower the cost of the medication. [ more ]
5 Ways Ozempic and Other New Weight-Loss Drugs Have Changed Health
New classes of weight-loss drugs are changing the way we think and talk about weight, dieting, and obesity.
These weight-loss drugs offer fast and easy weight loss and unexpected cardiac benefits, but high costs and poor accessibility pose challenges. [ more ]
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine. [ more ]
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine. [ more ]
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine. [ more ]